Affiliation: Imperial College
- Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconvertersAstrid Gall
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK
Retrovirology 10:8. 2013....
- Mouse DNA contamination in human tissue tested for XMRVMark J Robinson
Section of Infectious Diseases, Jefferiss Research Trust Laboratories, Imperial College London, St Mary s Campus, London, W2 1PG, UK
Retrovirology 7:108. 2010..To control for contamination, PCR assays to detect either mouse mitochondrial DNA (mtDNA) or intracisternal A particle (IAP) long terminal repeat DNA were run on all samples, owing to their very high copy number in mouse cells...
- Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trialGraham P Taylor
Department of GU Medicine and Communicable Diseases, Faculty of Medicine, Imperial College, London, UK
Retrovirology 3:63. 2006..We therefore conducted a randomised, double blind, placebo controlled study of six months combination therapy with these nucleoside analogues in sixteen patients...
- The development of vaginal microbicides for the prevention of HIV transmissionJonathan Weber
Wright Fleming Institute, Imperial College London, United Kingdom
PLoS Med 2:e142. 2005
- Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmissionJonathan Weber
Faculty of Medicine, Imperial College London, St Mary s Hospital, London, UK
AIDS 24:S27-39. 2010..Specifically, we consider the evidences for and against targeting HIV-uninfected individuals compared with enhanced HIV testing and treatment of HIV-infected individuals in terms of impact on viral transmission...
- Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC StudyTristan J Barber
St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
Antivir Ther 16:805-14. 2011..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort...
- Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill
Research Department of Infection and Population Health, UCL Medical School, London, UK
J Clin Epidemiol 63:1101-9. 2010..To ascertain the degree of loss to follow-up in a cohort and to identify its predictors...
- Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) StudyR J C Gilson
Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
HIV Med 11:152-60. 2010..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes...
- Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohortSarah Fidler
Imperial College, St Mary s Hospital, London, UK
AIDS 21:1283-91. 2007..To investigate the effect of a short course of HAART during primary HIV infection (PHI) on rate of CD4 cell and viral load change...
- Comparative potency of three antiretroviral therapy regimes in primary HIV infectionSarah Fidler
Department of GUM and Communicable Diseases, Wright Fleming Institute, Jefferiss Trust Laboratories, London, UK
AIDS 20:247-52. 2006..To best achieve the most rapid reduction in primary viraemia we compared three different ART regimens in PHI...
- Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infectionElizabeth Hamlyn
Kings College Hospital National Health Service Foundation Trust, London, United Kingdom
PLoS ONE 7:e43754. 2012..We compared plasma viral load (pVL) rebound after stopping ART initiated in primary (PHI) and chronic HIV infection (CHI)...
- Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected menEmma C Thomson
Department of Hepatology, Wright Fleming Institute, Faculty of Medicine, Imperial College London, London, UK
Gut 60:837-45. 2011..The aim of this study was to characterise the natural history of primary HCV in this setting and to assess host and viral factors which predict spontaneous clearance...
- Changes in viral load in people with virological failure who remain on the same HAART regimenAlessandro Cozzi-Lepri
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
Antivir Ther 8:127-36. 2003..To assess the rate of change in viral load and CD4 count over time in HIV-infected patients experiencing virological failure on a HAART regimen...
- Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr
MRC Clinical Trials Unit, London, UK
J Antimicrob Chemother 65:129-37. 2010..The aim of this study was to evaluate which demographic factors and concomitant drugs are associated with lopinavir and atazanavir plasma concentration...
- The effect of transmitted HIV-1 drug resistance on pre-therapy viral loadLinda Harrison
HIV and Infections Group, MRC Clinical Trials Unit, London, UK
AIDS 24:1917-22. 2010..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus...
- The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin
Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
HIV Med 10:35-43. 2009....
- Primary HIV infection: to treat or not to treat?Sarah Fidler
Department of GUM and HIV, Division of Medicine, Imperial College, UK
Curr Opin Infect Dis 21:4-10. 2008..The aim of this article is to review new data on the use of antiretroviral therapy in primary HIV infection...
- Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with menJulie Fox
Department of Genitourinary Medicine and Infectious Disease, Clinical Trials Centre, Winston ChurchillBuilding, Imperial College London, St Mary s Hospital Campus, London W2 1PG, UK
HIV Med 10:432-8. 2009..We explored the potential impact on HIV transmission-risk behaviour of PHI diagnosis in men who have sex with men (MSM)...
- Late diagnosis in the HAART era: proposed common definitions and associations with mortalityCaroline A Sabin
Research Department of Infection and Population Health, UCL Medical School, London, UK
AIDS 24:723-7. 2010....
- PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trialSheena McCormack
MRC Clinical Trials Unit, London, UK
Lancet 376:1329-37. 2010..PRO2000 vaginal gel was efficacious against HIV-1 transmission in studies in macaques; we aimed to assess efficacy and safety of 2% and 0·5% PRO2000 gels against vaginal HIV-1 transmission in women in sub-Saharan Africa...
- Clinical epidemiology of HIV-associated end-stage renal failure in the UKLoveleen Bansi
University College London Medical School, London, UK
AIDS 23:2517-21. 2009..To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom...
- Virological and immunological effects of short-course antiretroviral therapy in primary HIV infectionSarah Fidler
Wright Fleming Institute, Department of GUM and Communicable Diseases, Faculty of Medicine, Imperial College, St Mary s Hospital, London, UK
AIDS 16:2049-54. 2002..We sought to investigate whether a short course of antiretroviral therapy (SCART) at PHI was sufficient to preserve HIV-specific cellular immunity...
- DNA extraction columns contaminated with murine sequencesOtto Erlwein
Jefferiss Research Trust Laboratories, Section of Infectious Diseases, Imperial College London, London, United Kingdom
PLoS ONE 6:e23484. 2011..Thus, DNA purification columns can present problems when used to detect minute amounts of DNA targets by highly sensitive amplification techniques...
- Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in UgandaPontiano Kaleebu
Medical Research Council Programme on AIDS, Uganda Virus Research Institute, Entebbe, Uganda
J Infect Dis 185:1244-50. 2002..001), compared with subtype A, after adjusting for CD4 cell count at enrollment. In Africa, envelope subtype D is associated with faster disease progression, compared with subtype A...
- Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimenChristian Holkmann Olsen
Copenhagen HIV Programme, Section 044, Pavilion 1, DK 2650 Hvidovre, Denmark
AIDS 19:319-30. 2005..It is unknown whether the relationship between the HIV-RNA/CD4 cell count and risk of clinical disease continues to hold true for newer antiretroviral drugs approved without data from clinical endpoint trials...
- Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohortPontiano Kaleebu
Medical Research Council Uganda Virus Research Institute Research Unit on AIDS, Entebbe, Uganda
J Acquir Immune Defic Syndr 45:28-33. 2007..To determine whether there are differences in coreceptor use in subjects infected with HIV-1 envelope subtypes A and D that could explain the differences in progression rates between these subtypes in a rural Ugandan cohort...
- Resistance to HIV drugs in UK may be lower in some areasJulie M Fox
BMJ 332:179-80. 2006
- Long-term persistence of HIV-1 vaccine-induced CD4+CD45RA-CD62L-CCR7- memory T-helper cellsSunita S Balla-Jhagjhoorsingh
Department of Virology, Biomedical Primate Research Centre, 2280 GH Rijswijk, The Netherlands
AIDS 18:837-48. 2004..To determine in chimpanzees if candidate HIV-1 subunit protein vaccines were capable of eliciting long-lasting T-cell memory responses in the absence of viral infection, and to determine the specific characteristics of these responses...
- Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyPatricia Cane
BMJ 331:1368. 2005..To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom...
- Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck
Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
Antimicrob Agents Chemother 50:694-701. 2006..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype...
- Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA studyDaria Podlekareva
Hvidovre University Hospital, Kettegaard Alle 30, DK 2650 Hvidovre, Denmark
J Infect Dis 194:633-41. 2006..Limited data exist on factors predicting the development of opportunistic infections (OIs) at higher-than-expected CD4(+) cell counts in human immunodeficiency virus (HIV) type 1-infected adults...
- Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United KingdomJulie Fox
AIDS 22:666-8. 2008
- EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc ConsortiumPierre Alexandre Bart
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Vaccine 26:3153-61. 2008..Half of the 10 assessed responded in the ELISpot assay under stringent criteria, which informed the sample size for a DNA-NYVAC-C comparison to NYVAC-C alone...
- EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C aloneSheena McCormack
MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
Vaccine 26:3162-74. 2008..Of the 9 individuals with responses to envelope and other peptides, 8 were in the DNA-C group. These promising results suggest that DNA-C was an effective priming agent, that merits further investigation...